Protocol No 6 2019. September 25th 2019
Password-BoardProtocol-6-2019
Regenics AS have developed clinical proof of efficacy and safety in human 2 degree burn wounds for our products Collex® and Vernex®.
The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.
